Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study

Gary T. Ferguson, Alberto Papi, Antonio R Anzueto, Edward M. Kerwin, Christy Cappelletti, Elizabeth A. Duncan, Jack Nyberg, Paul Dorinsky

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219). Primary end-points were change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) and FEV1 area under the curve from 0-4 h (AUC0-4). Time to first and rate of moderate/severe exacerbations were assessed.BFF MDI 320/10 µg improved pre-dose trough FEV1versus FF MDI (least squares mean (LSM) 39 mL; p=0.0018), and BFF MDI 320/10 µg and 160/10 µg improved FEV1 AUC0-4versus BD MDI (LSM 173 mL and 157 mL, respectively; both p<0.0001) at week 24. BFF MDI 320/10 µg and 160/10 µg improved time to first and rate of moderate/severe exacerbations versus FF MDI. Treatments were well tolerated, with pneumonia incidence ranging from 0.5-1.4%.BFF MDI improved lung function versus monocomponents and exacerbations versus FF MDI in patients with moderate to very severe COPD.

Original languageEnglish (US)
JournalThe European respiratory journal
Volume52
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Budesonide
Chronic Obstructive Pulmonary Disease
Suspensions
Technology
Forced Expiratory Volume
Dry Powder Inhalers
Least-Squares Analysis
Metered Dose Inhalers
Formoterol Fumarate
Aerosols
Area Under Curve
Pneumonia
History
Lung
Incidence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Budesonide/formoterol MDI with co-suspension delivery technology in COPD : the TELOS study. / Ferguson, Gary T.; Papi, Alberto; Anzueto, Antonio R; Kerwin, Edward M.; Cappelletti, Christy; Duncan, Elizabeth A.; Nyberg, Jack; Dorinsky, Paul.

In: The European respiratory journal, Vol. 52, No. 3, 01.09.2018.

Research output: Contribution to journalArticle

Ferguson, Gary T. ; Papi, Alberto ; Anzueto, Antonio R ; Kerwin, Edward M. ; Cappelletti, Christy ; Duncan, Elizabeth A. ; Nyberg, Jack ; Dorinsky, Paul. / Budesonide/formoterol MDI with co-suspension delivery technology in COPD : the TELOS study. In: The European respiratory journal. 2018 ; Vol. 52, No. 3.
@article{298258b238844777bf890da4253a5d51,
title = "Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study",
abstract = "TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219). Primary end-points were change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) and FEV1 area under the curve from 0-4 h (AUC0-4). Time to first and rate of moderate/severe exacerbations were assessed.BFF MDI 320/10 µg improved pre-dose trough FEV1versus FF MDI (least squares mean (LSM) 39 mL; p=0.0018), and BFF MDI 320/10 µg and 160/10 µg improved FEV1 AUC0-4versus BD MDI (LSM 173 mL and 157 mL, respectively; both p<0.0001) at week 24. BFF MDI 320/10 µg and 160/10 µg improved time to first and rate of moderate/severe exacerbations versus FF MDI. Treatments were well tolerated, with pneumonia incidence ranging from 0.5-1.4{\%}.BFF MDI improved lung function versus monocomponents and exacerbations versus FF MDI in patients with moderate to very severe COPD.",
author = "Ferguson, {Gary T.} and Alberto Papi and Anzueto, {Antonio R} and Kerwin, {Edward M.} and Christy Cappelletti and Duncan, {Elizabeth A.} and Jack Nyberg and Paul Dorinsky",
year = "2018",
month = "9",
day = "1",
doi = "10.1183/13993003.01334-2018",
language = "English (US)",
volume = "52",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Budesonide/formoterol MDI with co-suspension delivery technology in COPD

T2 - the TELOS study

AU - Ferguson, Gary T.

AU - Papi, Alberto

AU - Anzueto, Antonio R

AU - Kerwin, Edward M.

AU - Cappelletti, Christy

AU - Duncan, Elizabeth A.

AU - Nyberg, Jack

AU - Dorinsky, Paul

PY - 2018/9/1

Y1 - 2018/9/1

N2 - TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219). Primary end-points were change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) and FEV1 area under the curve from 0-4 h (AUC0-4). Time to first and rate of moderate/severe exacerbations were assessed.BFF MDI 320/10 µg improved pre-dose trough FEV1versus FF MDI (least squares mean (LSM) 39 mL; p=0.0018), and BFF MDI 320/10 µg and 160/10 µg improved FEV1 AUC0-4versus BD MDI (LSM 173 mL and 157 mL, respectively; both p<0.0001) at week 24. BFF MDI 320/10 µg and 160/10 µg improved time to first and rate of moderate/severe exacerbations versus FF MDI. Treatments were well tolerated, with pneumonia incidence ranging from 0.5-1.4%.BFF MDI improved lung function versus monocomponents and exacerbations versus FF MDI in patients with moderate to very severe COPD.

AB - TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219). Primary end-points were change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) and FEV1 area under the curve from 0-4 h (AUC0-4). Time to first and rate of moderate/severe exacerbations were assessed.BFF MDI 320/10 µg improved pre-dose trough FEV1versus FF MDI (least squares mean (LSM) 39 mL; p=0.0018), and BFF MDI 320/10 µg and 160/10 µg improved FEV1 AUC0-4versus BD MDI (LSM 173 mL and 157 mL, respectively; both p<0.0001) at week 24. BFF MDI 320/10 µg and 160/10 µg improved time to first and rate of moderate/severe exacerbations versus FF MDI. Treatments were well tolerated, with pneumonia incidence ranging from 0.5-1.4%.BFF MDI improved lung function versus monocomponents and exacerbations versus FF MDI in patients with moderate to very severe COPD.

UR - http://www.scopus.com/inward/record.url?scp=85062190999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062190999&partnerID=8YFLogxK

U2 - 10.1183/13993003.01334-2018

DO - 10.1183/13993003.01334-2018

M3 - Article

C2 - 30220648

AN - SCOPUS:85062190999

VL - 52

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 3

ER -